Patrícia Zacharias, Daniéla Oliveira Magro, Milena Perussolo, Fernanda da Silva Barbosa Baraúna, Paulo Gustavo Kotze
{"title":"炎症性肠病的住院率、生物制剂使用率和手术率：拉丁美洲一家三级医院的公立和私立医疗系统之间的单中心比较分析。","authors":"Patrícia Zacharias, Daniéla Oliveira Magro, Milena Perussolo, Fernanda da Silva Barbosa Baraúna, Paulo Gustavo Kotze","doi":"10.1590/S0004-2803.24612023-140","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel diseases (IBD) have rising incidence and prevalence rates globally. In IBD, there are scarce stu-dies comparing differences between patients according to socioeconomic status. Our aim was to comparatively evaluate hospitalizations, use of biologics and rates of surgery in patients with IBD between public and private healthcare systems.</p><p><strong>Methods: </strong>Single-center retrospective cohort study in patients with IBD from a tertiary referral unit from Latin America, between 2015 and 2021. CD and UC patients were classified into two subgroups: public and private systems. Demographic characteristics, hospitalizations, need for surgery and biologics were compared.</p><p><strong>Results: </strong>A total of 500 patients were included, 322 with CD and 178 with UC. CD-related hospitalizations were frequently observed in both healthcare systems (76.28% in private and 67.46% in public). More than half of the patients had been submitted to one or more CD-related abdominal surgery, with no significant difference between the subgroups. Although there was no difference in the rates of use of biological therapy in CD subgroups, infliximab was more used in the public setting (57.69% vs 43.97%). There was no difference in UC-related hospitalizations between the subgroups (public 30.69% and private 37.66%) as well as the rates of colectomy (public: 16.83%, private: 19.48%). Biologics were prescribed almost twice as often in private as compared to public (45.45 vs 22.77%).</p><p><strong>Conclusion: </strong>There were no differences in the rates of hospitalization and abdominal surgery between the systems. In patients with UC, there was greater use of biological therapy in the private healthcare setting.</p><p><strong>Background: </strong>• In a tertiary IBD center in Latin America.</p><p><strong>Background: </strong>• More than half of the patients had been submitted to one or more CD-related abdominal surgical procedure.</p><p><strong>Background: </strong>• Between the two healthcare systems, there was no difference in the rates of use of biological therapy in patients with CD, and in UC-related hospitalizations.</p><p><strong>Background: </strong>• Biologics were prescribed almost twice as often in the private system as compared to the public in patients with UC.</p>","PeriodicalId":35671,"journal":{"name":"Arquivos de Gastroenterologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HOSPITALIZATION, USE OF BIOLOGICS AND SURGERY RATES IN INFLAMMATORY BOWEL DISEASES: A SINGLE-CENTRE COMPARATIVE ANALYSIS BETWEEN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS IN A TERTIARY UNIT FROM LATIN AMERICA.\",\"authors\":\"Patrícia Zacharias, Daniéla Oliveira Magro, Milena Perussolo, Fernanda da Silva Barbosa Baraúna, Paulo Gustavo Kotze\",\"doi\":\"10.1590/S0004-2803.24612023-140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Inflammatory bowel diseases (IBD) have rising incidence and prevalence rates globally. In IBD, there are scarce stu-dies comparing differences between patients according to socioeconomic status. Our aim was to comparatively evaluate hospitalizations, use of biologics and rates of surgery in patients with IBD between public and private healthcare systems.</p><p><strong>Methods: </strong>Single-center retrospective cohort study in patients with IBD from a tertiary referral unit from Latin America, between 2015 and 2021. CD and UC patients were classified into two subgroups: public and private systems. Demographic characteristics, hospitalizations, need for surgery and biologics were compared.</p><p><strong>Results: </strong>A total of 500 patients were included, 322 with CD and 178 with UC. CD-related hospitalizations were frequently observed in both healthcare systems (76.28% in private and 67.46% in public). More than half of the patients had been submitted to one or more CD-related abdominal surgery, with no significant difference between the subgroups. Although there was no difference in the rates of use of biological therapy in CD subgroups, infliximab was more used in the public setting (57.69% vs 43.97%). There was no difference in UC-related hospitalizations between the subgroups (public 30.69% and private 37.66%) as well as the rates of colectomy (public: 16.83%, private: 19.48%). Biologics were prescribed almost twice as often in private as compared to public (45.45 vs 22.77%).</p><p><strong>Conclusion: </strong>There were no differences in the rates of hospitalization and abdominal surgery between the systems. In patients with UC, there was greater use of biological therapy in the private healthcare setting.</p><p><strong>Background: </strong>• In a tertiary IBD center in Latin America.</p><p><strong>Background: </strong>• More than half of the patients had been submitted to one or more CD-related abdominal surgical procedure.</p><p><strong>Background: </strong>• Between the two healthcare systems, there was no difference in the rates of use of biological therapy in patients with CD, and in UC-related hospitalizations.</p><p><strong>Background: </strong>• Biologics were prescribed almost twice as often in the private system as compared to the public in patients with UC.</p>\",\"PeriodicalId\":35671,\"journal\":{\"name\":\"Arquivos de Gastroenterologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arquivos de Gastroenterologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/S0004-2803.24612023-140\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos de Gastroenterologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S0004-2803.24612023-140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景：在全球范围内，炎症性肠病（IBD）的发病率和流行率不断上升。关于 IBD，很少有研究比较不同社会经济地位的患者之间的差异。我们的目的是比较评估公立和私立医疗系统中 IBD 患者的住院率、生物制剂使用率和手术率：单中心回顾性队列研究：2015 年至 2021 年期间，拉丁美洲一家三级转诊机构的 IBD 患者。CD和UC患者被分为两个亚组：公立和私立系统。比较了人口统计学特征、住院情况、手术需求和生物制剂：共纳入 500 名患者，其中 CD 患者 322 名，UC 患者 178 名。在两个医疗系统中，与 CD 相关的住院治疗都很常见（私立医疗系统为 76.28%，公立医疗系统为 67.46%）。半数以上的患者接受过一次或多次与 CD 相关的腹部手术，但两个亚组之间没有明显差异。虽然 CD 亚组使用生物疗法的比例没有差异，但公立医院使用英夫利西单抗的比例更高（57.69% 对 43.97%）。不同亚组的 UC 相关住院率（公立 30.69% 和私立 37.66%）以及结肠切除率（公立 16.83%，私立 19.48%）均无差异。与公立医院相比，私立医院开具生物制剂处方的频率几乎是公立医院的两倍（45.45% 对 22.77%）：结论：不同系统的住院率和腹部手术率没有差异。在 UC 患者中，私立医疗机构使用生物疗法的比例更高：- 背景：拉丁美洲的一家三级 IBD 中心：- 背景：超过一半的患者接受过一次或多次与 CD 相关的腹部手术：- 在两个医疗系统中，CD患者使用生物制剂治疗的比例和UC相关住院治疗的比例没有差异：- 与公立医疗系统相比，私立医疗系统为 UC 患者开具生物制剂处方的频率几乎是公立医疗系统的两倍。
HOSPITALIZATION, USE OF BIOLOGICS AND SURGERY RATES IN INFLAMMATORY BOWEL DISEASES: A SINGLE-CENTRE COMPARATIVE ANALYSIS BETWEEN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS IN A TERTIARY UNIT FROM LATIN AMERICA.
Background: Inflammatory bowel diseases (IBD) have rising incidence and prevalence rates globally. In IBD, there are scarce stu-dies comparing differences between patients according to socioeconomic status. Our aim was to comparatively evaluate hospitalizations, use of biologics and rates of surgery in patients with IBD between public and private healthcare systems.
Methods: Single-center retrospective cohort study in patients with IBD from a tertiary referral unit from Latin America, between 2015 and 2021. CD and UC patients were classified into two subgroups: public and private systems. Demographic characteristics, hospitalizations, need for surgery and biologics were compared.
Results: A total of 500 patients were included, 322 with CD and 178 with UC. CD-related hospitalizations were frequently observed in both healthcare systems (76.28% in private and 67.46% in public). More than half of the patients had been submitted to one or more CD-related abdominal surgery, with no significant difference between the subgroups. Although there was no difference in the rates of use of biological therapy in CD subgroups, infliximab was more used in the public setting (57.69% vs 43.97%). There was no difference in UC-related hospitalizations between the subgroups (public 30.69% and private 37.66%) as well as the rates of colectomy (public: 16.83%, private: 19.48%). Biologics were prescribed almost twice as often in private as compared to public (45.45 vs 22.77%).
Conclusion: There were no differences in the rates of hospitalization and abdominal surgery between the systems. In patients with UC, there was greater use of biological therapy in the private healthcare setting.
Background: • In a tertiary IBD center in Latin America.
Background: • More than half of the patients had been submitted to one or more CD-related abdominal surgical procedure.
Background: • Between the two healthcare systems, there was no difference in the rates of use of biological therapy in patients with CD, and in UC-related hospitalizations.
Background: • Biologics were prescribed almost twice as often in the private system as compared to the public in patients with UC.
期刊介绍：
The journal Arquivos de Gastroenterologia (Archives of Gastroenterology), a quarterly journal, is the Official Publication of the Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia IBEPEGE (Brazilian Institute for Studies and Research in Gastroenterology), Colégio Brasileiro de Cirurgia Digestiva - CBCD (Brazilian College of Digestive Surgery) and of the Sociedade Brasileira de Motilidade Digestiva - SBMD (Brazilian Digestive Motility Society). It is dedicated to the publishing of scientific papers by national and foreign researchers who are in agreement with the aim of the journal as well as with its editorial policies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
